In today’s briefing:
- Yunkang Group Pre-IPO – Would Need to Prove Itself Post-COVID
- Shanghai Pulse Medical (博动医疗) Pre-IPO: Leading Image-Based FFR Player
Yunkang Group Pre-IPO – Would Need to Prove Itself Post-COVID
- Yunkang Group (YK HK) is looking to raise about US$200m in its upcoming Hong Kong IPO.
- Yunkang Group is a medical operation service provider in China and as per F&S, had a market share of 3.7% in China’s medical operation service market as per 2020 revenue.
- While it has managed to grow its on-site diagnostics centers, the firm has to prove that it can still thrive post-COVID.
Shanghai Pulse Medical (博动医疗) Pre-IPO: Leading Image-Based FFR Player
- Shanghai Pulse is a leading player in the FFR assessment in China. The company is looking to raise up to USD 200 m via a Hong Kong listing.
- We look at the company’s key products QFR, OFR and UFR. We also provide our thoughts on the investment thesis.
- We think the company has a decent investor backing and meanwhile we also highlight concerns on its management.
Before it’s here, it’s on Smartkarma
